1. ADIS R&D Profile. (2010). Ipilimumab. Drugs R D. 10(2), 97–110.
2. Awada, H. (2015). The development of Nivolumab, a humanized anti-human PD-1 monoclonal antibody. Regulatory Science of Pharmaceutical and Medical Devices, 46(3), 126–130.
3. Bavencio. (2017). Bavencio, highlights of prescribing information.
https://www.emdserono.com/content/dam/web/corporate/non-images/country-specifics/us/pi/bavencio-pi.pdf
. Accessed August 11, 2018.
4. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28(19), 3167–3175.
5. Bristol-Myers. (2009). Bristol-Myers Squibb to acquire Medarex.
http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-acquire-medarex
. Accessed August 3, 2015.